keyword
MENU ▼
Read by QxMD icon Read
search

Oncology, hematology

keyword
https://www.readbyqxmd.com/read/28809603/paraneoplastic-thrombocytopenia-cured-with-nephrectomy-and-vena-cava-thrombectomy-concurrent-hematology-and-oncology-management-conundrums
#1
Kevin R Melnick, Courtney Chang, Ana Antun, Shishir K Maithel, Viraj A Master
No abstract text is available yet for this article.
August 15, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28799485/monoclonal-antibodies-a-review
#2
Surjit Singh, Nitish Kumar, Pradeep Dwiwedi, Jaykaran Charan, Rimplejeet Kaur, Preeti Sidhu, Vinay Kumar Chugh
Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb, was first FDA approved therapeutic MAb for prevention of kidney transplant rejection. Since its approval in 1986, there has been decline in the further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of low grade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically...
August 9, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28795915/where-teachers-are-few-documenting-available-faculty-in-five-tanzanian-medical-schools
#3
Charles A Mkony, Ephata E Kaaya, Alex J Goodell, Sarah B Macfarlane
Background Faced with one of the lowest physician-to-population ratios in the world, the Government of Tanzania is urging its medical schools to train more physicians. The annual number of medical students admitted across the country rose from 55 in the 1990s to 1,680 approved places for the 2015/16 academic year. These escalating numbers strain existing faculty. Objective To describe the availability of faculty in medical schools in Tanzania. Design We identified faculty lists published on the Internet by five Tanzanian medical schools for the 2011/12 academic year and analyzed the appointment status, rank, discipline, and qualifications of faculty members...
December 2016: Global Health Action
https://www.readbyqxmd.com/read/28792782/emerging-antibody-drug-conjugates-for-treating-lymphoid-malignancies
#4
Anna Wolska-Washer, Pawel Robak, Piotr Smolewski, Tadeusz Robak
Antibody-drug conjugates (ADC) are monoclonal antibodies (Mabs) attached to biologically active drugs through specialized chemical linkers. They deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. These agents should improve the potency of chemotherapy by increasing the accumulation of the cytotoxic drug within or near the neoplastic cells with reduced systemic effects. Areas covered and methods: A literature review was conducted using the MEDLINE database, PubMed, for articles in English examining Mabs, B-cell receptor pathway inhibitors and immunomodulating drugs...
August 9, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28792663/rapid-infusion-of-rituximab-is-well-tolerated-in-children-with-hematologic-oncologic-and-rheumatologic-disorders
#5
M Brooke Bernhardt, Marietta M De Guzman, Amanda Grimes, Susan Kirk, Sheryl Nelson, Jessica Bergsbaken, Charles G Minard, Jenny McDade Despotovic
Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorders, and to determine the incidence of rate-related infusion reactions. Twenty patients enrolled in the study. All patients tolerated the rapid infusion of rituximab and no patient had an infusion-related reaction...
August 9, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28780190/targeting-eph-ephrin-system-in-cancer-therapy
#6
REVIEW
Alessio Lodola, Carmine Giorgio, Matteo Incerti, Ilaria Zanotti, Massimiliano Tognolini
It is well established that the Eph/ephrin system plays a central role in the embryonic development, with minor implications in the physiology of the adult. However, it is overexpressed and deregulated in a variety of tumors, with a primary involvement in tumorigenesis, tumor angiogenesis, metastasis development, and cancer stem cell regeneration. Targeting the Eph/ephrin system with biologicals, including antibodies and recombinant proteins, reduces tumor growth in animal models of hematological malignancies, breast, prostate, colon, head and neck cancers and glioblastoma...
July 18, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28770610/amino-acid-profiles-as-potential-biomarkers-for-pediatric-cancers-a-preliminary-communication
#7
Anna Synakiewicz, Malgorzata Sawicka-Zukowska, Natalia Adrianowska, Grazyna Galezowska, Joanna Ratajczyk, Anna Owczarzak, Lucyna Konieczna, Teresa Stachowicz-Stencel
AIM: Childhood cancer remains one of the main cause of death in the pediatric population. Amino acids (AAs) level alterations in plasma are considered to play a role in carcinogenesis and further course of the disease. METHODS: Seventy-seven children with cancer, including 47 with hematological and 30 with solid tumors were enrolled in this study and compared with healthy children. Twenty-two plasma-free AAs were determined by HPLC with fluorometric detection. RESULTS: The results revealed significant decrease in glutamine levels for oncological patients and significant increase in aspartic acid, glutamic acid, asparagine, serine, citrulline, alanine, GABA, tryptophan, methionine, valine, phenylalanine and isoleucine levels in cancer children versus control...
August 3, 2017: Biomarkers in Medicine
https://www.readbyqxmd.com/read/28761384/new-pd-l1-inhibitors-in-non-small-cell-lung-cancer-impact-of-atezolizumab
#8
REVIEW
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezolizumab, its landmark studies, and ongoing trials. Atezolizumab is the first programmed death ligand 1 (PD-L1) inhibitor to receive US Food and Drug Administration (FDA) approval for metastatic NSCLC patients who have progressed on frontline chemotherapy...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28761118/bortezomib-before-and-after-high-dose-therapy-in-myeloma-long-term-results-from-the-phase-iii-hovon-65-gmmg-hd4-trial
#9
H Goldschmidt, H M Lokhorst, E K Mai, B van der Holt, I W Blau, S Zweegman, K C Weisel, E Vellenga, M Pfreundschuh, M J Kersten, C Scheid, S Croockewit, R Raymakers, D Hose, A Potamianou, A Jauch, J Hillengass, M Stevens-Kroef, M S Raab, A Broijl, H W Lindemann, G M J Bos, P Brossart, M van Marwijk Kooy, P Ypma, U Duehrsen, R M Schaafsma, U Bertsch, T Hielscher, Le Jarari, H J Salwender, P Sonneveld
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0...
July 4, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28760292/proceedings-of-the-fourth-annual-meeting-of-the-society-of-hematologic-oncology
#10
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28750262/limited-diagnostic-value-of-a-multiplexed-gastrointestinal-pathogen-panel-for-the-detection-of-adenovirus-infection-in-an-oncology-patient-population
#11
Tracy McMillen, Yeon Joo Lee, Mini Kamboj, N Esther Babady
BACKGROUND: Diagnosis of Adenovirus infections in transplant patients may be accomplished using either plasma or stool samples. IVD-cleared multiplexed gastrointestinal (GI) PCR panels offer an option for rapid testing of stool samples but most only target Adenovirus (HAdV) types F40/41. OBJECTIVES: Given the potential significance of a positive adenovirus test in an immunocompromised patient, we sought to determine the frequency of type 40/41 in our patient population and the utility of a readily available multiplexed, FDA-cleared GI Panel for the detection of adenovirus infections...
July 8, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28748605/management-of-chemotherapy-induced-febrile-neutropenia-in-pediatric-oncology-patients-a-north-american-survey-of-pediatric-hematology-oncology-and-pediatric-infectious-disease-physicians
#12
Rochelle R Maxwell, Dana Egan-Sherry, Jonathan B Gill, Michael E Roth
BACKGROUND: Chemotherapy-induced febrile neutropenia (FN) is traditionally managed with hospital admission for parenteral antibiotics until neutropenia resolves. Recent studies have explored risk stratification and the safety of managing "low-risk" patients as outpatients. Few studies have directly assessed pediatric provider preferences for managing FN. PROCEDURE: We conducted a survey of practicing US and Canadian pediatric hematology/oncology (PHO) and pediatric infectious disease (PID) physicians to assess their FN management preferences using case scenarios with varying risk profiles...
July 27, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28747373/investigation-of-respiratory-syncytial-virus-outbreak-on-an-adult-stem-cell-transplant-unit-using-whole-genome-sequencing
#13
Yijun Zhu, Teresa R Zembower, Kristen E Metzger, Zhengdeng Lei, Stefan J Green, Chao Qi
A viral whole genome sequencing strategy, based on PCR amplification followed by Next-generation Sequencing, was used to investigate a nosocomial RSV-B outbreak in a hematology-oncology and stem cell transplant unit. RSV-B genomes from 16 patients and healthcare workers (HCWs) suspected to be involved in the outbreak were compared to RSV-B genomes acquired from outpatients during the same time period but epidemiologically unrelated to the outbreak. Phylogenetic analysis of the whole genome identified a cluster of 11 patients and HCWs with an identical RSV-B strain which were clearly distinct from strains recovered from individuals unrelated to the outbreak...
July 26, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28743264/recent-developments-in-immunotherapy-of-acute-myeloid-leukemia
#14
REVIEW
Felix S Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke, Marion Subklewe
The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the treatment of acute myeloid leukemia (AML) is hampered by various characteristics of the disease, including non-leukemia-restricted target antigen expression profile, low endogenous immune responses, and intrinsic resistance mechanisms of the leukemic blasts against immune responses. However, considerable progress has been made in this field in the past few years...
July 25, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28742692/oncologic-outcome-and-morbidity-in-the-elderly-rectal-cancer-patients-after-preoperative-chemoradiotherapy-and-total-mesorectal-excision-a-multi-institutional-and-case-matched-control-study
#15
Soo-Y Sung, Hong S Jang, Sung H Kim, Jae U Jeong, Songmi Jeong, Jin H Song, Mi J Chung, Hyeon M Cho, Hyung J Kim, Jun-Gi Kim, In K Lee, Jong H Lee
OBJECTIVE: To determine the toxicity and oncologic outcome of neoadjuvant chemoradiotherapy (CRT) followed by curative total mesorectal excision (TME) in the elderly (≥70 yrs) and younger (<70 yrs) rectal cancer patients. BACKGROUND: Sufficient data for elderly rectal cancer patients who received definitive trimodality have not been accumulated yet. PATIENTS AND METHODS: A total of 1232 rectal cancer patients who received neoadjuvant CRT and TME were enrolled in this study...
July 24, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28736021/infectious-complications-and-multidrug-resistant-bacteria-in-patients-with-hematopoietic-stem-cell-transplantation-in-the-first-12-months-after-transplant
#16
A César-Arce, P Volkow-Fernández, L M Valero-Saldaña, B Acosta-Maldonado, D Vilar-Compte, P Cornejo-Juárez
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been used as treatment in different hematologic and solid malignancies. The aim of this study was to describe the frequency of infectious complications, microbiology, and outcome in patients undergoing HSCT in Mexico during the pre-engraftment period and the impact on mortality rates at 12 months. METHODS: We conducted a retrospective study of all hematologic malignancies that received HSCT from January 2009 and December 2014, at an oncology reference center...
July 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28735365/an-update-on-the-use-of-immunotherapy-in-the-treatment-of-lymphoma
#17
REVIEW
Thomas U Marron, Matko Kalac, Joshua Brody
PURPOSE OF REVIEW: Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year. RECENT FINDINGS: In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells...
July 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28725926/the-intensive-care-medicine-research-agenda-on-critically-ill-oncology-and-hematology-patients
#18
REVIEW
Elie Azoulay, Peter Schellongowski, Michael Darmon, Philippe R Bauer, Dominique Benoit, Pieter Depuydt, Jigeeshu V Divatia, Virginie Lemiale, Maarten van Vliet, Anne-Pascale Meert, Djamel Mokart, Stephen M Pastores, Anders Perner, Frédéric Pène, Peter Pickkers, Kathryn A Puxty, Francois Vincent, Jorge Salluh, Ayman O Soubani, Massimo Antonelli, Thomas Staudinger, Michael von Bergwelt-Baildon, Marcio Soares
Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life-sustaining therapies for infectious or toxic chemotherapy-related events. Major changes include increased number of cancer patients admitted to the ICU with full-code status or for time-limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies...
July 19, 2017: Intensive Care Medicine
https://www.readbyqxmd.com/read/28719110/benefits-of-attending-a-weekend-childhood-cancer-survivor-family-retreat
#19
Lisa Bashore, Joyce Bender
PURPOSE: To explore the long-term benefits to families of childhood cancer survivors who attended a weekend childhood cancer survivor family retreat. DESIGN: Descriptive-qualitative study including families who had attended the weekend retreat at least once but not in the past 12 months, and who attend a large pediatric hematology and oncology cancer survivorship program in Texas. METHODS: A semistructured interview guide was used during three audio-taped focus groups to explore the benefits of having attended a weekend retreat...
July 18, 2017: Journal of Nursing Scholarship
https://www.readbyqxmd.com/read/28718335/variability-of-performance-status-assessment-between-patients-with-hematologic-malignancies-and-their-physicians
#20
Alexis D Leal, Cristine Allmer, Matthew J Maurer, Tait D Shanafelt, James R Cerhan, Brian K Link, Carrie A Thompson
This study was conducted to determine the incidence of inter-observer variability in Eastern Cooperative Oncology Group (ECOG) performance status (PS) rating between patients with leukemia and lymphoma and their physicians. ECOG PS was assessed at diagnosis by patients and their physicians and stratified by disease subtype, gender, age, disease stage and education. Association between patient- and physician-rated PS and overall survival (OS) was stratified by subtype and prognostic risk score. Overall, 65% of patients and physicians rated PS the same...
July 18, 2017: Leukemia & Lymphoma
keyword
keyword
285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"